Business Context and Reporting Period
This Form 8-K Current Report was filed by 60 Degrees Pharmaceuticals, Inc. on January 14, 2026. The report details a corporate action regarding the Company's capital structure, specifically a reverse stock split approved by stockholders on October 8, 2025, and filed with the Delaware Secretary of State on January 14, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event and does not contain financial performance data.
Material Changes
- Reverse Stock Split: The Company implemented a one-for-four (1:4) reverse stock split of its outstanding common stock.
- Effective Date: The split became effective at 12:01 a.m. Eastern Time on January 20, 2026.
- Share Conversion: Each four shares of issued and outstanding common stock were automatically combined and converted into one share.
- Fractional Shares: No fractional shares were issued; fractional amounts were rounded up to one whole share.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific financial risks. The primary purpose is to disclose the amendment to the Certificate of Incorporation and the resulting change in share count. A press release regarding the split was issued on January 15, 2026, but its content is not detailed in this text.
Investor Verification Checklist
- Verify the new share count and adjusted trading price on The Nasdaq Stock Market LLC under symbols SXTP (Common Stock) and SXTPW (Warrants) effective January 20, 2026.
- Confirm the treatment of fractional shares for specific holdings (rounded up to one whole share).
- Review the attached Certificate of Amendment (Exhibit 3.1) for complete legal terms of the reverse split.
- Check the Press Release (Exhibit 99.1) for additional context on the rationale for the split.